🧬 biology

The in-host treatment window: a closed-form phagocyte-recruitment threshold separates clearance failure from immunopathology — and the window does not collapse

This paper establishes a closed-form phagocyte-recruitment threshold that defines a structurally robust treatment window, separating bacterial clearance from chronic carriage and immunopathology within a minimal two-dimensional model of host-pathogen dynamics.

Original authors: Tian-Yu Wang

Published 2026-10-26

📖 6 min read🧠 Deep dive

CC BY 4.0

Original authors: Tian-Yu Wang

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ⚕️ This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer

When a bacterium invades a human body, the outcome is rarely decided by the germ alone. It is a three-way struggle involving the pathogen, the medicine used to fight it, and the host's own immune system. The immune system sends in specialized cells, like neutrophils, to engulf and destroy the invaders. This process is essential for survival, but it comes with a cost. The very inflammation that helps clear an infection can, if it becomes too intense, damage the body's own tissues. This creates a delicate balancing act for doctors: they must give enough medicine to kill the bacteria, but not so much that the immune system goes into overdrive and causes harm. For decades, scientists have tried to map this trade-off, often running complex computer simulations to see what happens under different treatment plans. However, these simulations usually produce graphs and tables that are hard to interpret, leaving a gap in understanding exactly how much immune activity is needed to clear an infection at a specific drug dose, and where the line is drawn between a cure and a dangerous reaction.

A researcher at Guangdong Peizheng College has now filled this gap by creating a simple, mathematical model that describes this battle with a clear, unambiguous rule. Instead of relying on endless computer runs, the study derives a specific formula that acts as a threshold. This formula tells us the exact amount of immune cell recruitment required to achieve a sterile state—where no bacteria remain—given a certain dose of antibiotics. The model treats the bacteria as a population that grows until it is stopped by either the drug or the immune cells, while the immune cells are recruited at a rate that can be boosted by the presence of bacteria. By analyzing how these two forces interact, the researcher proved that there is a precise "treatment window." If the immune recruitment is too low, the bacteria survive in a chronic, low-level state. If the recruitment is too high, the immune system itself becomes the disease, causing severe tissue damage.

The most striking finding of this work is that this treatment window does not collapse. In many complex systems, changing one variable can cause the safe zone to shrink until it disappears, leaving no solution. Here, the researcher shows that the lower edge of the window (the point where bacteria start to survive) and the upper edge (the point where inflammation becomes dangerous) are controlled by completely different sets of factors. The lower edge depends on how fast the bacteria grow and how effectively the immune cells kill them. The upper edge depends only on how much inflammation the body can tolerate before it turns pathological. Because these two boundaries are independent, widening one constraint does not necessarily narrow the other. The window remains open as long as the body's ability to kill bacteria is efficient enough to be contained within its tolerance for inflammation. This structural robustness means that for a wide range of conditions, a safe path exists where the infection is cleared without triggering a harmful immune storm.

The study also clarifies that the two ways a treatment can fail are fundamentally different. When the immune response is too weak, the system settles into a state of chronic carriage. The bacteria persist at moderate levels, and the patient may feel relatively stable, with only mild signs of inflammation. This is a quiet failure, but it allows the bacteria to survive and potentially spread. In contrast, when the immune response is too strong, the system crosses a threshold into inflammatory failure. Here, the immune cells multiply uncontrollably, leading to a runaway reaction that damages tissue. This is an acute, violent failure. The research shows that these two failures require different solutions. A chronic infection needs more drug or better immune support, while an inflammatory storm requires calming the immune response itself, because no amount of extra antibiotic can lower the level of immune cells once they have been recruited in excess.

Using a set of illustrative numbers based on known biological rates, the researcher mapped out this landscape. Without any drug, the model suggests that a recruitment rate of 3.0 units (measured in thousands of cells per microliter per hour) is needed to clear the infection, while the danger zone for tissue damage begins at 7.5 units. This leaves a safe window of 4.5 units. As the drug dose increases, the required recruitment rate drops, making the window wider and easier to navigate. The study calculated that at a baseline immune recruitment level, a specific drug dose is needed to tip the balance toward clearance. It also explored the cost of treatment, finding that there is an optimal dose that balances the speed of clearing the infection against the cost of the drug and the duration of inflammation, rather than simply using the highest possible dose.

The work distinguishes itself by providing a closed-form solution, meaning the boundaries are defined by a direct equation rather than a curve drawn from a computer simulation. This allows scientists to see immediately which factors matter. For instance, the study proves that the maximum effect of the drug does not change the upper limit of the safe window, only the lower limit. It also shows that the window's existence relies on a simple inequality: the bacteria's natural growth rate must be low enough that the immune system can control it before the inflammation becomes dangerous. If the bacteria grow too fast relative to the immune system's killing power, the window vanishes, and no amount of drug can save the patient without causing harm. However, with the parameters used in this study, the window is wide and stable.

This research offers a new way to think about treating infections, moving beyond trial-and-error dosing to a geometric understanding of the problem. It confirms that the trade-off between killing germs and avoiding self-harm is not a chaotic mess, but a structured space with clear boundaries. The findings suggest that clinicians are not just guessing between under-treatment and over-treatment; they are navigating a defined corridor. The lower wall of this corridor is the point where the bacteria win, and the upper wall is the point where the immune system wins too hard. The paper demonstrates that this corridor is resilient. As long as the immune system is efficient enough to kill the bacteria before the inflammation becomes unmanageable, a safe path exists. This insight provides a theoretical foundation for understanding why some infections are easy to treat while others are not, and why the same treatment can lead to a cure in one patient and a severe reaction in another, depending on where they sit within this invisible window.

Technical Summary: The In-Host Treatment Window

Problem Statement
Antibiotic dosing at an infected tissue site is constrained by a fundamental trade-off: insufficient drug allows bacterial persistence, while excessive recruitment of host inflammatory cells (phagocytes) to aid clearance risks causing tissue-damaging immunopathology. While previous within-host models have explored this clearance–immunopathology trade-off through numerical simulations or bifurcation analysis, they have failed to provide an explicit, closed-form threshold that defines the precise amount of immune recruitment required for bacterial sterility at a given drug dose. Consequently, the geometric structure of the "therapeutic window"—bounded by clearance failure on one side and immunopathology on the other—remains opaque regarding its parameter dependencies and structural robustness.

Methodology
The author employs a minimal two-dimensional ordinary differential equation (ODE) model describing the interaction between bacterial load ( $B$ ) and phagocyte population ( $P$ ).

Bacterial Dynamics: Bacteria grow logistically with a drug-reduced growth rate, $\gamma_{eff}(d)$ , defined by an $E_{max}$ pharmacodynamic function. They are killed by phagocytes via either mass-action kinetics ( $\kappa PB$ ) or Michaelis–Menten kinetics ( $\kappa_M \frac{PB}{h+B}$ ).
Phagocyte Dynamics: Phagocytes are recruited via a baseline influx ( $\lambda$ ) and bacteria-triggered recruitment ( $\rho B$ ), with autocatalytic amplification ( $\sigma P$ ) and linear decay ( $\delta P$ ). The net decay rate is defined as $\mu = \delta - \sigma$ .
Analytical Approach: The study derives a closed-form recruitment threshold ( $\lambda^\dagger$ ) for the stability of the sterile steady state ( $B=0$ ). It analyzes the system's bifurcation structure, specifically identifying transcritical bifurcations where the sterile state exchanges stability with an endemic equilibrium. The model is calibrated using illustrative parameter anchors from existing literature (e.g., Antia et al., Stossel, Regoes) to generate a phase diagram in the drug dose ( $d$ ) vs. recruitment influx ( $\lambda$ ) plane.

Key Contributions and Results

Closed-Form Recruitment Threshold:
The paper proves a main theorem establishing that the sterile steady state is locally asymptotically stable if and only if the recruitment influx $\lambda$ exceeds a closed-form threshold:
$\lambda > \lambda^\dagger(d) = \frac{\gamma_{eff}(d) \cdot \mu}{\kappa}$
(with a corresponding form for Michaelis–Menten killing). At $\lambda = \lambda^\dagger(d)$ , the system undergoes a transcritical bifurcation, birthing a stable endemic equilibrium (chronic carriage).
Three-Regime Phase Diagram:
By combining the sterility threshold $\lambda^\dagger(d)$ with a pathology boundary $\lambda_P = \mu \cdot P_{crit}$ (where $P_{crit}$ is the phagocyte density causing tissue damage), the author defines three distinct regimes:
- Region I (Sterile Window): $\lambda^\dagger(d) < \lambda \le \lambda_P$ . Bacteria are cleared without pathological inflammation.
- Region II (Chronic Carriage): $\lambda < \lambda^\dagger(d)$ . Bacteria persist at a stable endemic level; this represents clearance failure via a transcritical transition.
- Region III (Inflammatory Failure): $\lambda > \lambda_P$ . The system is sterile but suffers from immunopathology (excessive phagocyte density), or, if autocatalysis exceeds decay ( $\sigma \ge \delta$ ), exhibits exponential runaway divergence.
Structural Robustness and Non-Collapse:
A central finding is that the therapeutic window does not collapse under parameter variation. The lower edge ( $\lambda^\dagger$ ) and upper edge ( $\lambda_P$ ) are governed by disjoint parameter combinations:
- $\lambda^\dagger$ depends on $(\gamma_{eff}, \mu, \kappa)$ .
- $\lambda_P$ depends on $(\mu, P_{crit})$ .
  Crucially, the relative window width is independent of the net decay rate $\mu$ . The window only collapses if the bacterial growth rate exceeds the maximum possible killing capacity at the pathology threshold ( $\gamma > \kappa P_{crit}$ ), a condition the author shows is excluded by their physiological anchors.
Distinct Failure Modes:
The paper distinguishes two qualitatively different failure modes flanking the window:
- Undertreatment (Region II): A dynamical transition to a stable endemic state (chronic carriage) with mild inflammation.
- Hyperinflammation (Region III): An exogenous threshold crossing into pathological densities or a mathematical runaway, representing acute immunopathology. The author notes that these require different interventions (increasing drug/recruitment vs. controlling recruitment source).
Dose-Recruitment Trade-offs:
The analysis derives the minimum effective dose ( $d_{min}$ ) required for sterility at a given recruitment level and identifies a cost-optimal dose that balances clearance speed against drug expenditure and inflammation. The study also demonstrates that the "window" is a steady-state property; transient pulse dosing may fail to clear infection if the recruitment condition is not sustained.

Significance and Claims
The paper claims to close a gap in within-host modeling by providing the first explicit, closed-form description of the therapeutic window in a dose–recruitment phase diagram. Unlike previous numerical bifurcation studies that return curves without explicit formulas, this work reveals the parameter decoupling that ensures the window's structural robustness. The author argues that this geometric insight clarifies why the window exists and why it is resistant to collapse, provided the bacterial growth rate is contained by the killing capacity at the pathology threshold.

The author maintains a modest scope, acknowledging that their results are based on a minimal model with illustrative parameter anchors rather than clinical fitting. They explicitly state that the model excludes resistance evolution, spatial heterogeneity, and adaptive immunity. The significance lies in the theoretical framework: it provides a tractable, analytic tool to distinguish between clearance failure and immunopathology, suggesting that the "dose is wrong" is an oversimplification that conflates two distinct dynamical transitions requiring different clinical remedies.

Technical Summary: The In-Host Treatment Window

More like this